Abstract
Objectives. The aim of this study was to determine the manner in which the level of exhaled nitric oxide (FENO) influences the atopic status in children with asthma. Methods. The study included 92 asthmatic children (aged 5-18 years) admitted on the Pediatric Clinic of “Grigore Alexandrescu” Emergency Clinical Hospital for Children. The atopic status was evaluated through anamnesis, clinical examination and laboratory determination of serum eosinophils and total Ig E. All children underwent measurement of FENO. Results. Children with atopic asthma had higher levels of FENO than children with nonatopic asthma. The FENO values correlate with eosinophilia and high values of immunoglobulin E. Conclusion. FENO is a useful marker for the evaluation of airway inflammation in children with atopic asthma.
Highlights
Asthma is a chronic, heterogeneous disease with an incomplete known pathogeny which incriminates especially the persistent airway inflammation
The distribution of allergic asthma on the two subgroups did not identify statistical differences according to age group, to the presence of atopy, rhinitis or family history positive for atopy (p>0.05, Table no 1)
The mean values of the measured parameters FENO, eosinophils and Ig E differ according to the diagnosis of allergic asthma, being statistically significant higher in this subgroup than in the subgroup with non-allergic asthma (p < 0.05, Table 1)
Summary
Heterogeneous disease with an incomplete known pathogeny which incriminates especially the persistent airway inflammation. Nitric oxide is a marker that evaluates this particular inflammation and has been more and more used as a biomarker for the various phenotypes of asthma [1]. FENO correlates with the atopic status and quantifies the severity of airway inflammation. High levels of nitric oxide are pathognomonic for eosinophilic inflammation [2]. Studies have shown that patients with atopic asthma have higher levels of FENO [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
